Filing Flows › Travere Therapeutics (TVTX) › Total net product sales revenue
Travere Therapeutics (TVTX) Total net product sales revenue by quarter
Travere Therapeutics' Total net product sales revenue was $220M in Q3 2026 (third quarter 2026), +36% from Q2 2026. Over the last 7 quarters it ranged from $75.9M (Q1 2025) to $220M (Q3 2026).
| Quarter | Total net product sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $220M | +36% | +95% |
| Q2 2026 | $161M | +30% | +70% |
| Q1 2026 | $124M | -2% | +64% |
| Q4 2025 | $127M | +12% | — |
| Q3 2025 | $113M | +19% | — |
| Q2 2025 | $94.8M | +25% | — |
| Q1 2025 | $75.9M | — | — |
Q3 2026 at a glance
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Travere Therapeutics' Total net product sales revenue?
Travere Therapeutics' Total net product sales revenue was $220M in Q3 2026 (third quarter 2026), +36% from Q2 2026.
How has Travere Therapeutics' Total net product sales revenue changed?
Over the last 7 quarters it ranged from $75.9M (Q1 2025) to $220M (Q3 2026).